Analyzing Lexaria Bioscience (LEXX) & Its Competitors

Lexaria Bioscience (NASDAQ:LEXX) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Lexaria Bioscience to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk.

Profitability

This table compares Lexaria Bioscience and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Lexaria Bioscience Competitors	-2,381.20%	-218.66%	-15.76%

Earnings & Valuation

This table compares Lexaria Bioscience and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lexaria Bioscience	$710,000.00	-$11.90 million	-0.80
Lexaria Bioscience Competitors	$3.56 billion	$3.19 billion	548.11

Lexaria Bioscience’s peers have higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Lexaria Bioscience has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Lexaria Bioscience’s peers have a beta of -3.76, indicating that their average share price is 476% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Lexaria Bioscience and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1	0	1	0	2.00
Lexaria Bioscience Competitors	7777	13864	25737	1034	2.41

Lexaria Bioscience currently has a consensus target price of $22.50, suggesting a potential upside of 452.83%. As a group, “Pharmaceuticals” companies have a potential upside of 23.77%. Given Lexaria Bioscience’s higher possible upside, research analysts clearly believe Lexaria Bioscience is more favorable than its peers.

Summary

Lexaria Bioscience peers beat Lexaria Bioscience on 9 of the 13 factors compared.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.